Physician profile
Aaron Walter Pumerantz
NPI 1407088438
$11,443.30
in general payments reported to CMS, 2019-2025
26 companies · $2,430 in 2025
The $2,430 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,081 · 2020: $744 · 2021: $842 · 2022: $1,100 · 2023: $1,690 · 2024: $2,557 · 2025: $2,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,676.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,686.66 | 2019-2025 | |
| Amgen INC. | $1,714.60 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,653.36 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,007.08 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $615.21 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $426.29 | 2022-2025 | Saphnelo |
| Lilly USA, LLC | $384.76 | 2019-2025 | Taltz |
| Glaxosmithkline, LLC. | $372.78 | 2019-2025 | Benlysta |
| Pfizer INC. | $355.67 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $322.47 | 2019-2025 | Orencia |
| Genzyme Corporation | $136.51 | 2025 | |
| Genentech USA, INC. | $131.34 | 2019-2024 | Actemra |
| Kiniksa Pharmaceuticals International, Plc | $124.56 | 2024 | Arcalyst |
| Biocompatibles, INC. | $91.72 | 2019 | |
| Celgene Corporation | $83.68 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrocision, INC. | $83.67 | 2024 | Tenjet |
| Mallinckrodt Hospital Products INC. | $43.52 | 2021-2023 | Acthar |
| Fresenius Kabi USA, LLC | $34.10 | 2023 | Idacio |
| Horizon Therapeutics Plc | $28.35 | 2020-2022 | |
| Daiichi Sankyo INC. | $27.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.17 | 2019 | |
| Alvogen INC | $22.73 | 2024 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.93 | 2024 | Cyltezo |
| Organon LLC | $20.02 | 2024 | |
| Merck Sharp & Dohme LLC | $16.58 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Pumerantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.